Part A of this trial will evaluate the safety and tolerability of a single unilateral administration of one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Sensorineural Hearing Loss, Bilateral
Part A of this trial will evaluate the safety and tolerability of a single unilateral administration of one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
-
University of Iowa, Iowa City, Iowa, United States, 52242
Boston Children's Hospital, Boston, Massachusetts, United States, 02115
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19146
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Akouos, Inc.,
Kathy Reape, MD, STUDY_DIRECTOR, Akouos, Inc.
2028-10